We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, Lantheus Holdings’ earnings of $1.37 per share surpassed the Zacks Consensus Estimate by 42.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average being 50%.
Let’s see how things have shaped up prior to this announcement.
Factors at Play
On the fourth-quarter 2022 earnings call in February, Lantheus Holdings’ management confirmed that it has been registering a robust uptick in sales of its PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used with PET or computed tomography. The favorable adoption of PSMA PET with PYLARIFY is expected to have continued in the first quarter of 2023 on the back of its positive impact of the PSMA-targeted PET imaging on the U.S. prostate cancer community. This is likely to have considerably driven the to-be-reported quarter’s revenues.
On the same call, Lantheus Holdings’ management confirmed that its partner Curium is currently seeking to bring the first commercially available F 18-based PSMA PET imaging agent to Europe in June and had submitted their marketing authorization application to the European Medicines Agency for approval. Lantheus Holdings’ partnership with GE Healthcare regarding the Phase 3 clinical trial of F 18-based PET diagnostic radiopharmaceutical flurpiridaz also looks promising. These developments buoy our optimism about the stock.
Lantheus Holdings’ injectable ultrasound enhancing agent, DEFINITY, has been registering strong growth over the past few months, despite navigating market dynamics. Management’s observation about DEFINITY being the continued preferred ultrasound-enhancing agent in patient echocardiography exams looks promising for product sales in the first quarter.
In April, Lantheus Holdings announced that the FDA had granted Fast Track designation for Lu-PNT2002 for the treatment of metastatic castration-resistant prostate cancer. In February, the company presented positive data regarding the potential benefits of piflufolastat F 18 on decisions on treatment plans. The same month, Lantheus Holdings acquired Knoxville-based Cerveau Technologies, Inc. Per management, the buyout is expected to diversify its radiopharmaceutical diagnostic imaging agent pipeline to now include the most widely-used Tau PET imaging agent in Alzheimer’s disease. Hence, it is likely to provide the company with an extensive option for academic collaborations and pharmaceutical partnerships. These raise our optimism about the stock.
The Estimate Picture
For fourth-quarter 2022, the Zacks Consensus Estimate of $280.7 million for total revenues calls for an uptick of 34.4% from the prior-year reported figure.
The consensus estimate for adjusted earnings per share is pegged at $1.29, indicating an improvement of 32.9% from the prior-year reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP has higher chances of beating estimates. This is not the case here.
Earnings ESP: Lantheus Holdings has an Earnings ESP of -0.58%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +5.17% and a Zacks Rank of 2. CAH has an estimated long-term growth rate of 11.6%.
Cardinal Health’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, with the average surprise being 6.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BellRing Brands, Inc. (BRBR - Free Report) has an Earnings ESP of +2.40% and is a Zacks #2 Rank stock. BRBR has an estimated long-term growth rate of 12.7%.
BellRing Brands’ earnings surpassed estimates in all the trailing four quarters, with the average surprise being 19.1%.
Surrozen, Inc. (SRZN - Free Report) has an Earnings ESP of +13.86% and sports a Zacks Rank of 1 at present. SRZN has an estimated long-term growth rate of 38.4%.
Surrozen’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 43.9%.
Image: Bigstock
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
Lantheus Holdings, Inc. (LNTH - Free Report) is scheduled to release first-quarter 2023 results on May 4, before the opening bell.
In the last reported quarter, Lantheus Holdings’ earnings of $1.37 per share surpassed the Zacks Consensus Estimate by 42.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on all occasions, the average being 50%.
Let’s see how things have shaped up prior to this announcement.
Factors at Play
On the fourth-quarter 2022 earnings call in February, Lantheus Holdings’ management confirmed that it has been registering a robust uptick in sales of its PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used with PET or computed tomography. The favorable adoption of PSMA PET with PYLARIFY is expected to have continued in the first quarter of 2023 on the back of its positive impact of the PSMA-targeted PET imaging on the U.S. prostate cancer community. This is likely to have considerably driven the to-be-reported quarter’s revenues.
On the same call, Lantheus Holdings’ management confirmed that its partner Curium is currently seeking to bring the first commercially available F 18-based PSMA PET imaging agent to Europe in June and had submitted their marketing authorization application to the European Medicines Agency for approval. Lantheus Holdings’ partnership with GE Healthcare regarding the Phase 3 clinical trial of F 18-based PET diagnostic radiopharmaceutical flurpiridaz also looks promising. These developments buoy our optimism about the stock.
Lantheus Holdings, Inc. Price and EPS Surprise
Lantheus Holdings, Inc. price-eps-surprise | Lantheus Holdings, Inc. Quote
Lantheus Holdings’ injectable ultrasound enhancing agent, DEFINITY, has been registering strong growth over the past few months, despite navigating market dynamics. Management’s observation about DEFINITY being the continued preferred ultrasound-enhancing agent in patient echocardiography exams looks promising for product sales in the first quarter.
In April, Lantheus Holdings announced that the FDA had granted Fast Track designation for Lu-PNT2002 for the treatment of metastatic castration-resistant prostate cancer. In February, the company presented positive data regarding the potential benefits of piflufolastat F 18 on decisions on treatment plans. The same month, Lantheus Holdings acquired Knoxville-based Cerveau Technologies, Inc. Per management, the buyout is expected to diversify its radiopharmaceutical diagnostic imaging agent pipeline to now include the most widely-used Tau PET imaging agent in Alzheimer’s disease. Hence, it is likely to provide the company with an extensive option for academic collaborations and pharmaceutical partnerships. These raise our optimism about the stock.
The Estimate Picture
For fourth-quarter 2022, the Zacks Consensus Estimate of $280.7 million for total revenues calls for an uptick of 34.4% from the prior-year reported figure.
The consensus estimate for adjusted earnings per share is pegged at $1.29, indicating an improvement of 32.9% from the prior-year reported number.
What Our Model Suggests
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP has higher chances of beating estimates. This is not the case here.
Earnings ESP: Lantheus Holdings has an Earnings ESP of -0.58%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering, as these have the right combination of elements to beat on earnings this reporting cycle.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +5.17% and a Zacks Rank of 2. CAH has an estimated long-term growth rate of 11.6%.
Cardinal Health’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, with the average surprise being 6.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BellRing Brands, Inc. (BRBR - Free Report) has an Earnings ESP of +2.40% and is a Zacks #2 Rank stock. BRBR has an estimated long-term growth rate of 12.7%.
BellRing Brands’ earnings surpassed estimates in all the trailing four quarters, with the average surprise being 19.1%.
Surrozen, Inc. (SRZN - Free Report) has an Earnings ESP of +13.86% and sports a Zacks Rank of 1 at present. SRZN has an estimated long-term growth rate of 38.4%.
Surrozen’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 43.9%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.